Topical Therapies in Psoriasis

Abstract

Topical therapy as monotherapy is useful in psoriasis patients with mild disease. Topical agents are also used as adjuvant for moderate-to-severe disease who are being concurrently treated with either ultraviolet light or systemic medications. Emollients are useful adjuncts to the treatment of psoriasis. Use of older topical agents such as anthralin and coal tar has declined over the years. However, they are cheaper and can still be used for the treatment of difficult psoriasis refractory to conventional treatment. Salicylic acid can be used in combination with other topical therapies such as topical corticosteroids (TCS) and calcineurin inhibitors for the treatment of thick limited plaques to increase the absorption of the latter into the psoriatic plaques. Low- to mid-potent TCS are used in facial/flexural psoriasis and high potent over palmoplantar/thick psoriasis lesions. The addition of noncorticosteroid treatment can also facilitate the avoidance of long-term daily TCS. Tacrolimus and pimecrolimus can be used for the treatment of facial and intertriginous psoriasis. Tazarotene is indicated for stable plaque psoriasis usually in combination with other therapies such as TCS. Vitamin D analogs alone or in combination with TCS are useful in stable plaques over limbs and palmoplantar psoriasis. Topical therapies for scalp psoriasis include TCS, Vitamin D analogs, salicylic acid, coal tar, and anthralin in various formulations such as solutions, foams, and shampoos. TCS, vitamin D analogs, and tazarotene can be used in the treatment of nails psoriasis.

Keywords: Psoriasis, therapeutic guidelines, topical therapy

Introduction

In India, the prevalence of psoriasis varies from 0.44%–2.8%. The majority of these patients have mild-to-moderate disease and can be treated with topical agents which provide potential therapeutic efficacy and limit the adverse effects of the systemic treatment to the target tissue.

Aim of Therapy

The aim of the therapy is to minimize the extent and severity of psoriasis to the point at which it is no longer detrimental to a patient’s quality of life.

Indications

Topical therapy is the treatment of choice in patients with psoriasis affecting <10% body surface area (BSA) (mild psoriasis). It can also be used for psoriasis affecting sensitive areas such as the face, flexures, and genitals.

Topical agents are also used as adjuvant for:
- Psoriasis affecting >10% BSA (moderate/severe psoriasis) on ultraviolet (UV) light or systemic medications
- Refractory palmoplantar or scalp psoriasis.

Factors Which Influence Topical Therapy

Patient factors

Treatment regimens must be individualized according to the patient’s age, sex, occupation, understanding, and the available resources.

Disease factors

Treatment also depends on the site of the lesions and their extent and severity. Assessment of severity should include the patient’s own perception of disability, the need for treatment, and an objective assessment of extent and severity.

Vehicle

The choice of vehicle can significantly alter the use and penetration of medications, and hence the therapeutic effect. There is a vast array of vehicles including creams,

Access this article online

Website: www.idoj.in
DOI: 10.4103/2229-5178.209622

Quick Response Code:

How to cite this article: Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J 2017;8:235-45.

Received: September, 2016. Accepted: November, 2016.
gels, solutions, foams, sprays, shampoos, and lotions. Different vehicles are indicated for different body sites. Scalp is commonly involved in psoriasis and requires gel, solutions, or foams that are not as messy as ointments and creams. Elsewhere, patients may prefer a less greasy preparation such as a cream during the daytime, and an ointment which is more effective but less cosmetically appealing at night.

**Occlusion**

Occlusive therapy, in which the skin is covered, often with a plastic membrane, enhances the penetration of topical agents such as corticosteroids. The occlusive dressings trap heat and moisture, hydrating and macerating the skin and forcing the medication through the plaques.\(^{3,4}\)

**Combination therapy**

Combination therapy may be indicated when monotherapy fails, for example, the combination of super potent steroids and calcipotriene.\(^{6,7}\) However, when using multiple topical agents, it is important to be aware of possible compatibility issues, for example, salicylic acid inactivates calcipotriene.\(^{9}\) On the other hand, anthralin requires salicylic acid for its chemical stability.\(^{9}\) When it is desirable to use multiple topical agents, patients may be instructed to apply the various medications at separate times throughout the day.

Topical agents can be used intermittently or continuously. More potent agents must be used on a short-term basis to allow for response, and then patients should be instructed to use these agents intermittently for long-term management. This strategy may reduce the risk of side effects.

Alternatively, patients who require continuous topical therapy should be instructed to use the least potent agent that allows for disease control or be transitioned to a topical agent that is associated with the lowest long-term risk.

All patients on topical therapy should be examined regularly to look for the development of side effects at the earliest.

**Adherence to Therapy**

Adherence to topical treatment is a major issue, being generally poor in the majority of the patients. In compliance studies, 39% of the patients admitted to nonadherence with topical therapy.\(^{10}\) Adherence has been seen to improve with simple regimens and once a day therapy. Moreover, realistic treatment outcomes should be discussed with patients, and they should be encouraged to participate in decision making.

**Emollients and Moisturizers**

Emollients form the backbone of therapy for psoriasis. They are a valuable first-line treatment because dry skin is common in psoriasis and adds to its irritability.

**Mechanism of action**

Moisturizers help in normalizing hyperproliferation, differentiation, and apoptosis. They have anti-inflammatory effects in addition improving barrier function. This helps in combating the stresses generated in the skin and Koebner’s phenomenon.\(^{11}\)

Hence, emollients moisturize dry skin, reduce scaling, ease itching, soften cracks, and improve penetration of other topical agents.\(^{12}\) They may also slow down the rate of epidermal turnover.

**Efficacy**

Emollients do not work as a monotherapy but as an adjuvant to topical/systemic therapy.

- There are two randomized, placebo-controlled trials of aloe vera gel for the treatment of mild-to-moderate psoriasis with one showing better efficacy compared to placebo\(^ {13}\) and the other showing no benefit over placebo\(^ {14}\).
- It has been reported for chronic plaque psoriasis that water-in-oil emollients are useful as steroid-sparing agent.\(^ {15}\) The hydration of the stratum corneum leads to an enhanced delivery of topical corticosteroids (TCS).

**Vehicles and preparations**

Emollients come in many different forms such as creams, ointments, lotion, bath oils, and soap substitutes. Creams and ointments are preferable to lotions. They tend to be thicker, more occlusive, and therefore more effective.\(^ {15}\) Ointments are more suited for extra dry, thickened, or brittle skin and can be used at night. Lighter, less greasy creams or lotions are ideal for daytime use. Creams, ointments, or lotions should be used liberally and frequently such that the skin does not dry out (dehydrating). The commonly used emollients are petroleum jelly, liquid paraffin, and mineral oils.

**Adverse effects**

Emollients can cause a few side effects such as irritant dermatitis, allergic contact dermatitis, fragrance allergy, stinging, cosmetic acne, and pigmentary disorders.\(^ {16}\)

There are no contraindications to the use of emollients. These are considered to be safe during pregnancy and lactation as well as for pediatric use.

**Anthralin (Dithranol)**

Over the years, anthralin has been shown to be one of the most effective topical treatments of stable plaque psoriasis. It may be used as a Short contact anthralin therapy (SCAT) for the treatment of localized, scaly plaques of psoriasis on the body or the scalp that have not cleared with other treatments.
Mechanism of action

Anthralin reduces keratinocyte proliferation, prevents T-cell activation, and restores cell differentiation, probably through mitochondrial dysfunction.\[^{[17]}\] In addition, production of free radicals may contribute to its effect.\[^{[18]}\]

Modes of application of anthralin

Although anthralin has been used as an overnight therapy, we recommend that it be used only as SCAT in which high concentration of anthralin, 1% or greater, is applied for approximately 20 min to 1 h before removal.\[^{[19]}\]

In another regimen, anthralin in a concentration of 1% or greater is applied for 5 min on the 1st day. Daily applications continue with increases up to 5 min every other day until patients develop mild irritation. The period of application is then maintained until clearing.

Efficacy

There is limited placebo-controlled trial data. In a systematic review of topical preparations for the treatment of psoriasis, it was found that dithranol reduced psoriasis severity scores at 4–8 weeks significantly more than placebo.\[^{[20]}\] Short contact (30 min) and overnight therapy with 1%, 2%, and 3% dithranol ointment have shown similar efficacy, suggesting SCAT to be more convenient and practical.\[^{[21]}\] Anthralin, similar to monotherapy, appears to have lower efficacy than more potent TCS or Vitamin D derivatives.\[^{[22]}\] Other randomized controlled trials have found that Vitamin D analogs are equally effective as short contact dithranol regimen but with better tolerability and acceptability of Vitamin D analogs.\[^{[23,24]}\]

Adverse effects

The most common side effect of anthralin is skin irritation, which is dose related. Anthralin also stains lesional and adjoining skin, hair, nails, clothing, and other objects, with which the patients come into contact.\[^{[25]}\] Attempts to reduce these using low concentrations SCAT and concomitant steroid therapy have been only partially successful. Triethanolamine applied after the removal of anthralin, prevents staining and irritation by neutralizing any anthralin residue remaining on the skin.\[^{[26]}\] Chlorine bleach can be used to remove stains from household items.\[^{[27]}\] If the psoriatic plaques are well-defined, the surrounding normal skin can be protected by the use of an agent such as zinc oxide paste. It should be applied with caution to the face and intertriginous areas due to the risk of skin irritation.

No systemic toxicity has been reported even following long-term application of anthralin. Anthralin is pregnancy Category C.

For children: Use with caution.

Salicylic acid is frequently added to improve the stability of anthralin and to increase its penetration and efficacy.\[^{[28]}\]

Preparations

1. Derobin ointment containing dithranol 1.15%, coal tar solution 5.3%, salicylic acid 1.15%, and petrolatum base
2. Micanol is a 1% anthralin formulation in a temperature sensitive vehicle (microcapsules).\[^{[29]}\] It is removed by washing with cold water which leads to re-crystallization. It is effective in short and long contact regimens. It is particularly useful for scalp psoriasis
3. New formulations in emulsifying ointment base with 0.1% w/w ascorbyl palmitate as an anti-oxidant are stable for up to 52 weeks.\[^{[30]}\]
4. Dithranol, in an emulsifying oil base (bio-wash oil), is useful for scalp psoriasis.\[^{[31]}\]
5. Liposomal dithranol (lipogel) is an effective formulation with less irritation and staining.\[^{[32]}\]

Coal Tar

Coal tar is frequently used as a part of an inpatient or daily dressing regimen. Its use in conjunction with UVB, the Goeckerman regimen, is well recognized.\[^{[33]}\] Coal tar probably suppresses DNA synthesis, thereby reducing the hyperproliferation of keratinocytes.\[^{[34]}\]

Efficacy

The success of coal tar has been demonstrated on chronic plaque psoriasis, palmoplantar psoriasis, and scalp psoriasis. Most chronic plaques improve after 1 month and patients remain in remission for longer than that with other psoriasis topical treatments.\[^{[35]}\]

- A recent Cochrane review of efficacy of coal tar preparations supports the use of coal tar products in the treatment of psoriasis, although the level of evidence is not strong. Coal tar is well tolerated with a few side effects\[^{[36]}\]
  - Coal tar was as effective as calcipotriol after 12 weeks of treatment in a prospective study, however, Vitamin D analog was better tolerated and had a faster onset of action.\[^{[37]}\]
  - Similarly, Khandpur et al. compared the efficacy of coal tar—salicylic acid ointment versus calcipotriol/betamethasone dipropionate (BMD) ointment and concluded that both the treatment modalities were comparable in efficacy at the end of 12 weeks, although the calcipotriol/BMD ointment had quicker onset of action.\[^{[38]}\]
  - Other comparative studies have found calcipotriol superior to coal tar treatment.\[^{[39]}\]

Side effects

The use of tar has waned due to its poor side effects profile and superior efficacy of alternative topical therapies.\[^{[40]}\]

Adverse effects of coal tar include odor, staining, irritant contact dermatitis, erythema, stinging, folliculitis, and formation of keratoacanthomas.\[^{[41]}\]
Occupational coal tar exposure is a recognized carcinogen. However, there is no evidence of carcinogenesis reported in patients with psoriasis who have had treatment with coal tar.[42,43]

Treatment with PUVA and coal tar is not recommended due to the risk of skin cancer.[43]

Coal tar (Category C) may be used during pregnancy.[44]

Coal tar should be used with caution in the pediatric population.

**Newer formulations of coal tar**

Recently new formulations of coal tar, ranging from 1% to 15% have been developed. They are claimed to be nonstaining, nonodorous, and easily spreadable. Their efficacy is superior to conventional coal tar preparations and equal to topical ultrapotent steroid preparations.[45-47]

**Salicylic Acid**

Salicylic acid is a topical keratolytic agent that has been used for many years in the topical treatment of psoriasis. It can be used in combination with TCS and calcineurin inhibitors to increase the absorption of the latter into the psoriatic plaques.

**Mode of action**

Salicylic acid leads to desquamation of corneocytes through two pathways. It reduces intercellular cohesiveness of the horny cells by dissolving the intercellular cement material. Moreover, it reduces the pH of the stratum corneum, thereby increasing hydration and softening.[48]

**Efficacy**

While there are no placebo-controlled studies verifying the efficacy and safety of salicylic acid used alone, salicylic acid is often combined with other topical therapies, including TCS[46] and immunomodulators[49] in the therapy of psoriasis. Salicylic acid significantly increases the penetration rate of TCS because of its keratolytic effects.[49]

Steroid–salicylic acid combination can be used as first line of treatment on thick, scaly plaques.

Salicylic acid can be applied to areas with thick stratum corneum including palms, soles, and scalp. It can also be used on the trunk. Its use should be avoided on genitals, the mucous membrane, and the eyes.

Tiplica et al. found that the combination of mometasone furoate (0.1%) and salicylic acid (5%) was more effective than monotherapy with mometasone furoate (0.1%).[49]

The addition of salicylic acid to dithranol formulations improves the clinical efficacy of dithranol because of the antioxidant properties of salicylic acid.[51]

It can be applied as a paste or in creams, ointments, and lotions in concentration of 2%-6%.

**Adverse effects**

The major problem in the topical treatment of psoriasis with salicylic acid is the potential chronic or acute systemic intoxication with the symptoms of oral mucosa burning, frontal headache, central nervous system symptoms, metabolic acidosis, tinnitus, nausea, and vomiting.[52,53]

These symptoms may occur in the topical treatment of large body surfaces, especially in children.[54,55] Even lethal cases are reported;[56] therefore, a concentration greater than 10% and an application on larger surfaces, especially in children, are not suitable. Salicylic acid should not be applied to more than 20% of the BSA.

If larger surfaces require a salicylic acid treatment for initial keratolysis, a sequential treatment is useful (e.g., affected areas in the upper part of the body at night and the lower part of the body in the morning). Careful clinical monitoring helps to avoid salicylic acid intoxication.

It should be noted calcipotriol is inactivated by salicylic acid.[57]

Salicylic acid blocks UV light, and therefore should be applied after phototherapy.[48]

**Pregnancy and children**

Salicylic acid can be safely used for localized psoriasis in pregnancy; however, because of a greater risk of systemic absorption and toxicity, salicylic acid should be avoided in children.

**Topical Immunomodulators**

**Calcineurin inhibitors**

Calcineurin inhibitors are approved for use in mild-to-moderate atopic dermatitis only; any use in psoriasis is off label.

**Mechanism of action**

Calcineurin inhibitors inhibit the action of calcineurin phosphatase and block the production of inflammatory substances that are thought to be important in causing skin lesions in psoriasis.[58]

There are two topical preparations of calcineurin inhibitors, namely, tacrolimus ointment (0.03% and 0.1%) and pimecrolimus cream (1%).

**Tacrolimus and pimecrolimus**

Neither tacrolimus ointment[59] nor pimecrolimus cream[60] appears to be effective for treating plaque-type psoriasis when simply applied as commercially available preparations. This is probably because of large molecular size and the inability to penetrate thick, psoriatic plaques. However, the penetration can be enhanced by occlusion[60] or by combining these agents with salicylic acid.[50]
**Efficacy**

A recent review of the efficacy of topical calcineurin inhibitors (TCIs) in psoriasis has concluded that topical tacrolimus (0.1%), and to a lesser extent, pimecrolimus (1%) have efficacy in the treatment of psoriasis. These are safe and effective in patients with facial, intertriginous, and genital psoriasis.[61]

However, they are less potent than 0.005% calcipotriol or 0.1% betamethasone valerate.[62]

Newer vehicle of topical tacrolimus, a 0.3% gel and 0.5% cream, have been developed to improve its penetration into thick psoriatic plaques.[63]

**Adverse effects**

The most common adverse event reported with the use of tacrolimus and pimecrolimus is a stinging sensation, which is usually transient.[61] Irritation is more significant with tacrolimus than pimecrolimus.

There is a theoretical risk of cancer with long-term use of TCI, and a black box warning has been added to the labels of these medications.[64] As a result, new Food and Drug Administration (FDA) recommendations state that topical immunomodulators should not be used as long-term treatment, over large surface areas, or in children under the age of 2 years.

**Use of calcineurin inhibitors in pregnancy and pediatric population**

Both topical tacrolimus and pimecrolimus have been labeled Category C, but are generally not considered teratogenic due to their low systemic absorption.[65] Both these medicines are found in human milk, and hence are not recommended for nursing mothers.

Topical tacrolimus (0.03%) ointment and topical pimecrolimus cream are approved for patients as young as 2 years with atopic dermatitis. There is minimal evidence regarding the safety and efficacy of these medications in young patients with psoriasis. A recent single-center, open label trial has demonstrated that tacrolimus ointment is an effective treatment for psoriasis on the face or intertriginous areas in children with minimal side effects.[66]

**New calcineurin inhibitor**

**Sirolimus**

It is a newly developed topical immunomodulator. It has recently been investigated as a possible treatment for chronic plaque psoriasis.[67]

**Topical Retinoids**

**Tazarotene**

Tazarotene, a Vitamin A derivative, is the first synthetically developed retinoid indicated for the topical treatment of psoriasis. It is available as a gel or cream at concentration of 0.1% or 0.05%. Tazarotene is indicated for stable plaque psoriasis usually in combination with TCS and calcipotriene. It has been demonstrated to be an effective maintenance therapy for psoriasis. Tazarotene under occlusion is also effective it the treatment of nail psoriasis.

**Mechanism of action**

Tazarotene selectively binds to β and γ retinoic acid on the cell membrane of keratinocytes and is then transported to the nucleus, altering transcription of genes in keratinocytes. This results in reduced epidermal hyperproliferation, normalizing keratinocyte differentiation, and decreasing inflammation.[68]

**Efficacy**

- In a recent study, tazarotene 0.1% and 0.05% cream applied daily for 12 weeks was found to be more effective than vehicle in plaque psoriasis.[69]
- Tazarotene (0.1% and 0.05%) has been found to be as effective as flucinonide with greater remission rate and more irritation than the latter.[70]
- In a recent observer-blinded, randomized controlled trial conducted in India, 0.1% tazarotene cream was as effective as clobetasol propionate for palmoplantar psoriasis.[71]
- Its efficacy has been demonstrated to be comparable to calcipotriene 0.005% ointment[72] and 5% coal tar ointment.[73]
- The combination of tazarotene with mometasone demonstrated greater efficacy and more rapid and sustained improvement than corticosteroids monotherapy.[74]
- Once daily application of 0.1% tazarotene for 12–24 weeks has been shown to improve nail psoriasis including onycholysis, hyperkeratosis, pitting, and salmon patches.[75]

**Adverse effects**

The most common side effect of tazarotene is localized irritation.[69] The use of cream, low concentration, alternate day application and short contact (30–60 min) application may help alleviate such symptoms.[76] Concomitant use of TCS may also minimize symptoms.

Tazarotene must not be used in sensitive areas such as the face, flexures and genitals.[77]

The FDA has issued a caution regarding the use of tazarotene and exposure to sunlight, and patients are advised to use sunscreens when using tazarotene. When it is combined with phototherapy, the dosimetry might need to be lowered to prevent skin burning.

**Use of tazarotene in pregnancy and children**

Tazarotene is contraindicated in pregnancy, Category X, because of the theoretical risk of teratogenicity.[65] Children tolerate topical retinoids very well. Topical retinoids
are, therefore, considered safe and efficacious in the pediatric populations, although no specific trials have been conducted in children and it remains an off-label use of the medication.

**New retinoids**

**Bexarotene**

Bexarotene gel is being studied as a potential treatment for psoriasis. It selectively binds nuclear retinoid X receptor.

Bexarotene gel 1% has been found to be effective in treating mild-to-moderate plaque psoriasis as monotherapy[78] as well as in combination with narrowband UVB therapy.[79]

**Topical Corticosteroids**

TCS are universally used in the management of all grades of psoriasis. They are used as monotherapy when the disease is mild and as a complement to systemic therapy in patients with moderate-to-severe psoriasis.

**Mechanism of action**

Corticosteroids are vasoconstrictive, antiproliferative, anti-inflammatory, and immunosuppressive. They bind to intracellular corticosteroid receptor and regulate gene transcription of numerous genes, particularly those that code for proinflammatory cytokines.

**Selecting potency of topical corticosteroids**

While selecting the potency of corticosteroids and its vehicle, one should take into consideration the disease severity, the site being treated, patient preference, as well as the age of the patient. Penetration correlates inversely with the thickness of the stratum corneum[80] and is greatly increased on areas such as the scrotum and face [Table 1].[81]

Potent and superpotent TCS may be used for stubborn, thick, and chronic plaques.

**Efficacy**

Clinical efficacy of Class I TCS such as clobetasol and halobetasol is well established in the treatment of plaque psoriasis.[82,83] Treatment is generally twice a day for approximately 2 weeks followed by an intermittent dosing regimen to preserve remission. Similarly, midpotent TCS such as fluticasone propionate has also been found to be effective in plaque psoriasis.[84]

Different regimens have been tried for maintenance therapy with TCS. Three consecutive applications (12 h apart) once a week therapy with BMD ointment has been used for maintenance of remission.[85] Another maintenance regimen of clobetasol propionate twice weekly achieved remission for an average of 4 months in 75% of treated patients.[86]

TCS in the form of lotions, solutions, and foams are effective in scalp psoriasis.[75,87,88] Potent topical steroids such as clobetasol propionate can be used for the treatment of psoriasis involving nail bed and/or nail matrix.[75]

**Limitations**

TCS are often used for longer period. This can lead to tachyphylaxis.

The side effects of TCS[89] include skin atrophy striae, telangiectasia, or secondary infection. Therefore, potent TCS should not be used on the face or intertriginous sites. Systemic adverse events occur when TCS are used for prolonged periods of time or at doses higher than commonly prescribed. Prolonged use of potent TCS may result in its significant systemic absorption which can lead to HPA axis suppression, Cushing’s syndrome, and hyperglycemia.

Another possible concern is the rebound phenomenon after abrupt discontinuation of TCS.

TCS usage in higher doses can lead to a pustular flare of psoriasis on their discontinuation.

**Topical corticosteroids use in pregnancy and in pediatric population**

TCS are labeled as pregnancy Category C.[90] Their safety in breastfeeding is unknown.

Infants and young children are at greater risk for side effects due to their higher skin surface to body mass ratio. Both growth retardation and suppression of the HPA axis have been documented in children more frequently than in older population.[91] As a result of systemic absorption, regular assessment of growth in children using TCS for long-term is recommended.

**New vehicle formulations for topical corticosteroids**

New formulations have been developed in the form of spray, shampoos, and foams in an effort to enhance the delivery of TCS. All of the newer topical clobetasol propionate formulations produce clearing of psoriasis for a large proportion of patients within 2–4 weeks with response, safety, and tolerability rates that are at least

| Site                   | Potency of TCS                  | Vehicle               |
|------------------------|---------------------------------|-----------------------|
| Face                   | Low and medium potency          | Creams               |
| Intertriginous areas   | Low and medium potency          | Creams               |
| Trunk and extremities  | Moderate to potent              | Ointment, spray, foam|
| Palms and soles        | Potent to superpotent           | Ointment, solution, lotion, foam, gel, shampoo |
| Scalp                  | Moderate to high                |                       |

TCS: Topical corticosteroids
Vitamin D Analogs

Vitamin D analogs provide a useful adjunct in the treatment of chronic plaque psoriasis. They are also useful in the treatment of nail psoriasis and chronic plaque psoriasis of the scalp. It should be used under occlusion for nail psoriasis. Synthetic Vitamin D analogs have been developed (by modification of the side chain) to enhance the antipsoriatic effect of Vitamin D₃ and reduce their hypercalcemic action (because they are rapidly transformed into inactive metabolites).

Mechanism of action

Vitamin D analogs bind to the intracellular Vitamin D receptor which then binds to and regulates the genes involved in epidermal proliferation, inflammation, and keratinization.[94]

There are three Vitamin D analog preparations available to treat psoriasis, namely, calcipotriene (calcipotriol in Europe), calcitriol, and tacalcitol.

Calcipotriene

It is a synthetic Vitamin D analog available as 0.005% (5 mg/g) cream, ointment, and scalp lotion. Although it is as potent as 1, 25 dihydroxycholecalciferol in the regulation of cell proliferation and differentiation, it is at least 200 times less potent in its effects on calcium metabolism.[94]

Efficacy

It has similar efficacy to Class 2 and 3 TCS but has relatively fewer side effects. In comparison to superpotent TCS, calcipotriene has delayed onset of action but results in longer disease-free interval.[95] As monotherapy, the maximal response usually requires 2 months of therapy.[96]

- The Cochrane systematic review provided evidence that twice daily calcipotriene is a safe and effective treatment for plaque psoriasis[97]
- It is more effective than other Vitamin D analogs (tacalcitol or calcitriol), short contact dithranol therapy,[97] and 15% coal tar[98]
- Calcipotriene solution has been found to be effective for the treatment of scalp psoriasis[98]
- Combination of the calcipotriene and TCS in ointment and solution forms has proven superior to either agent used alone[99]
- A new calcipotriene/BMD aerosol foam formulation has been found to be safe and effective in patients with extensive psoriasis vulgaris.[100]

Calcitriol

It is a synthetic form of the active metabolite of Vitamin D.[96] It is available as an ointment only (3 mg/g).

Efficacy

Multicenter and randomized clinical trials have demonstrated long-term safety and efficacy of calcitriol.[101] It is less potent than BMD, 0.05% but induces longer remission than the latter.

Tacalcitol

It is a synthetic Vitamin D analog available as 4 mg/g ointment and lotion, applied once daily.

Efficacy

Clinical studies have shown tacalcitol ointment to be a safe and effective long-term treatment for chronic plaque psoriasis with no systemic side effects and good tolerability in sensitive areas.[102] It is, however, less potent than calcipotriene.[103] The combination with clobetasol propionate in lacquer for the treatment of nail psoriasis where tacalcitol ointment under occlusion was applied twice daily on weekdays and the steroid lacquer on weekends has been found to be effective.[73]

Adverse effects

Vitamin D analogs are relatively safe with few side effects. The most common adverse effect is skin irritation on or around the psoriasis plaques.[102] Face and intertriginous areas are especially prone to irritation. Calcitriol and tacalcitol have a better tolerability on sensitive areas as compared to calcipotriene, and therefore serve as better options in these areas.[102,104]

Systemic side effects such as hypercalcemia, hypercalciuria, and parathyroid hormone suppression are very rare if the maximum dose is not exceeded: 100 g/week for calcipotriene, 210 g/week for calcitriol, and 70 g/week for tacalcitol.[105]

Calcitriol may have greater effects on serum calcium in comparison to other analogs.[106]

Vitamin D analogs are contraindicated in patients already suffering from hypercalcemia. Patients with renal impairment need to be observed carefully.

Calcipotriene is a relatively unstable molecule that is inactivated by an acid pH.[107] It can be combined with halobetasol ointment or cream or with 5% tar gel, however, it is degraded when mixed with 6% salicylic acid, 12% ammonium lactate or hydrocortisone-17 valerate ointment.[108]

Topical Vitamin D analog use in pregnancy and pediatric population

Treatment with Vitamin D analogs during pregnancy is rated Category C.[105] Vitamin D analogs have not been
found to be teratogenic in animals, although no clinical data on humans has been reported. The use of calcipotriene for the treatment of psoriasis in children is effective, and the dose should not exceed 50 g/week.

**Newer Vitamin D analogs**

Newer Vitamin D analogs including maxacalcitol, paricalcitol, and becocalcidiol are being studied for the treatment of psoriasis. They appear to be promising drugs for the treatment of plaque psoriasis.

**Conclusion**

Topical therapies are the backbone of management of psoriasis. They are safe and well tolerated by the patients. TCS and Vitamin D analogs are the treatment of choice among the various topical agents available for psoriasis. TCI can be used as steroid-sparing agents on the face and intertriginous areas. Tazarotene can be used as an effective maintenance therapy.

New vehicle formulations such as gels, lotions, solutions, shampoos, foams, etc., have been developed to improve the aesthetics, and thereby the patient compliance which is of utmost importance for optimum results.

New insights in the pathogenesis of psoriasis have enabled identification of new therapeutic targets. Target-based topical agents are being developed and tested. Moreover, advancement in nanotechnology has led to the possibility of improving the efficacy of topical agents and minimizing their side effects. The advent of newer molecules and newer drug delivery systems will significantly expand the therapeutic armamentarium for the treatment of psoriasis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-601.
2. van de Kerkhof PC, Barker J, Griffiths CE, Kragballe K, Mason J, Menter A, et al. Psoriasis: Consensus on topical therapies. J Eur Acad Dermatol Venereol 2008;22:859-70.
3. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 1993;18:504-6.
4. Patel T, Bhutani T, Busse KL, Koo J. Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: A 6-week bilaterally controlled, investigator-blinded trial. Cutis 2011;88:149-54.
5. Volden G, Kragballe K, van de Kerkhofe PC, Aberg K, White RJ. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing v/s twice daily treatment with clobetasol propionate alone. J Dermatol Treat 2001;12:141-4.
6. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (Davobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93.
7. Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag 2008;4:141-8.
8. Del Rosso J. Pharmacotherapy updates: Current therapies and research for common dermatologic conditions. The many roles of salicyclic acid. Skin Aging 2005;13:38-42.
9. Green PG, Forbes DR, Kennedy CTC. The stability of dithranol in various bases. Br J Dermatol. 1985; 113 (s29):26.
10. van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Nethrlands. Dermatology 2000;200:292-8.
11. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol 2008;26:380-6.
12. Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol 2009;10 Suppl 1:7-12.
13. Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study. Trop Med Int Health 1996;1:505-9.
14. Paulsen E, Kortholm L, Brandrup F. A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol 2005;19:326-31.
15. Witten PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001;76:943-9.
16. Nola I, Kostovik K, Kotrulja L, Lugovic L. The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol Croat 2003;11:80-7.
17. McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in respiratory competent mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005;19:1012-4.
18. Mahrle G. Dithranol. Clin Dermatol 1997;15:723-37.
19. Fleischmann HE. Short-contact anthralin therapy for psoriasis. West J Med 1987;147:461.
20. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: A systematic review. Br J Dermatol 2002;146:351-64.
21. Jones SK, Campbell WC, Mackie RM. Out-patient treatment of psoriasis: Short contact and overnight dithranol therapy compared. Br J Dermatol 1985;113:331-7.
22. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RR, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266-71.
23. Hutchinson PE, Marks R, White J. The efficacy, safety and tolerability of calcipotriol 3 microg/o ment in the treatment of plaque psoriasis: A comparison with short-contact dithranol. Dermatology 2000;201:139-45.
24. de Korte J, van der Valk PG, Sprangers MA, Damstra RJ, Kunkeler AC, Lijnen RL, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: Quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol 2008;158:375-81.
25. Loffler H, Effendy I, Happle R. Skin susceptibility to dithranol: Contact allergy or irritation? Eur J Dermatol 1999;9:32-4.
Torsekar and Gautam: Topical therapies in psoriasis

26. Ramsay B, Lawrence CM, Bruce JM, Shuster S. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990;23:73-6.

27. Wang JC, Krazmien RJ, Dahlheim CE, Patel B. Anthralin removal. J Am Acad Dermatol 1986;15(5 Pt 1):951-5.

28. Knechze M, Rahm C, Landersjö L. The influence of salicylic acid on the *in vitro* release of anthralin from an oil in water cream. Acta Pharm Nord 1990;2:313-8.

29. Völdén G, Björnberg A, Tegner E, Pedersen NB, Arlés UB, Agren S, *et al.* Short-contact treatment at home with micanol. Acta Derm Venereol 1992;172:20-2.

30. Weller PJ, Newman CM, Middleton KR, Wicker SM. Stability of a novel dithranol ointment formulation, containing ascorbyl palmitate as an anti-oxidant. J Clin Pharm Ther 1990;15:419-23.

31. Wulf-Woesten A, Ohiendör D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004;17:91-7.

32. Saraswat A, Agarwal R, Katara OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatol Treat 2007;18:40-5.

33. Goecckerman W. Treatment of psoriasis. Northwest Med 1925;24:229-31.

34. Arbiser JL, Govindarajan B, Battie TE, Lynch R, Frank DA, Ushio-Fukai M, *et al.* Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antispotioric coal tar. J Invest Dermatol 2006;126:1396-402.

35. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999;41:51-9.

36. Sluetsky JB, Clark RA, Remedios AA, Klein PA. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 2010;9:1258-64.

37. Sharma V, Kaur I, Kumar B. Calcipotriol versus coal tar: A prospective randomized study in stable plaque psoriasis. Int J Dermatol 2003;42:834-8.

38. Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar-salicic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol 2014;59:579-83.

39. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994;131:673-7.

40. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.

41. Lin AN, Moses K. Tar revisited. Int J Dermatol 1985;24:216-8.

42. Volden G, Björnberg A, Tegner E, Pedersen NB, Arlés UB, Agren S, *et al.* Triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1986;15(5 Pt 1):951-5.

43. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with atopic dermatitis treated with coal tar. A 25-year follow-up study. J Am Acad Dermatol 1980;3:612-5.

44. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980;1:732-5.

45. Lam J, Poliška JE, Dohal MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59:295-315.

46. Frankel AJ, Zeichner JA, Del Rosso JQ. Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: Case report and clinical implications. J Clin Aesthet Dermatol 2010;3:42-5.

47. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol 2010;76:612-21.

48. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1990;28:16-24.

49. Tiplica GS, Salavastru CM. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:905-12.

50. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005;141:43-6.

51. Runne U. Anthralin-salicic acid therapy of psoriasis. Cignolin-salicic acid-vaseline treatment and Lasan paste in a right-left comparison. Hautarzt 1974;25:199-200.

52. Zesch A. Short and long-term risks of topical drugs. Br J Dermatol 1986;115 Suppl 31:63-70.

53. Chapman BJ, Proudfoot AT. Adult salicylate poisoning: Deaths and outcome in patients with high plasma salicylate concentrations. Q J Med 1989;72:699-707.

54. Pec J, Strmienová M, Palencárová E, Pullmann R, Funiaková S, Visnovsky P, *et al.* Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 1992;50:307-9.

55. Germann R, Schindera I, Kuch M, Seitz U, Altmeyer S, Schindera F. Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris. Hautarzt 1996;47:624-7.

56. Taylor JR, Halprin KM. Percutaneous absorption of salicylic acid. Arch Dermatol 1975;111:740-3.

57. van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 2003;16:69-83.

58. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: Mechanisms of action. Eur J Dermatol 2002;12:618-22.

59. Zonneveld IM, Rubins A, Jablonska S, Doboz A, Ruzicka T, Kind P, *et al.* Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998;134:1101-2.

60. Gupta AK, Chow M. Pimecolimus: A review. J Eur Acad Dermatol Venereol 2003;17:493-503.

61. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg 2014;18:8-14.

62. Kreuter A, Sommer A, Hyun J, Bräutigam M, Brockmeyer NH, Altmeyer P, *et al.* pimecolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: A double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-43.

63. Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, *et al.* 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 2006;86:29-33.

64. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed 2006;8:8.
intertriginous areas in pediatric patients. Pediatr Dermatol 2007;24:76-80.
67. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial. Br J Dermatol 2005;152:758-64.
68. Ducic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998;39(4 Pt 2):S129-33.
69. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-7.
70. Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, et al. Once-daily tazarotene gel versus twice-daily fluorocarbon-oil cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38(5 Pt 1):705-11.
71. Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: An observer-blinded randomized controlled study. Indian J Dermatol 2011;56:40-3.
72. Kaur I, Dogra S, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J Dermatol Venereol Leprol 2008;74:471-4.
73. Kumar U, Kaur I, Dogra S, De D, Kumar B. Topical tazarotene vs. coal tar in stable plaque psoriasis. Clin Exp Dermatol 2010;35:482-6.
74. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001;40:210-2.
75. Handa S. Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol 2010;76:634-44.
76. Veraldi S, Chimenti S. Short contact therapy with tazarotene in psoriasis of the scalp. Br J Dermatol 1994;130:483-7.
77. Wollina U. Genital ulcers in a psoriasis patient using topical betamethasone. Dermatology 2006;212:235-7.
78. Breneman D, Sheth P, Berger V, Naini V, Stevens V. Phase II clinical trial of baxarotene gel 1% in psoriasis. J Drugs Dermatol 2007;6:501-6.
79. Margiocco MA, Pandya K, Dombrovsky V, Christiansen L, Wong Y, Gottlieb AB. A randomized double blinded, vehicle controlled, bilateral comparison trial of baxarotene gel 1% versus vehicle gel in combination with NB-UVB phototreatment for moderate to severe psoriasis vulgaris. J Am Assoc Dermatol 2006;54:115-8.
80. Vickers CF. Existence of reservoir in the stratum corneum. Experimental proof. Arch Dermatol 1963;88:20-3.
81. Feldman RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967;48:181-3.
82. Bernhard J, Whitmore C, Guzzo C, Kantor J, Kalb RE, Ellis C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: Report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol 1991;25(6 Pt 2):1170-4.
83. Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991;25(6 Pt 2):1153-6.
84. Olsen EA. Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. Cutis 1996;57(2 Suppl: 57-61.
85. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: A double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183:269-74.
86. Svanholm H, Larsson L, Frederiksen B. Intermittent topical treatment of psoriasis with clobetasol propionate. Curr Med Res Opin 1982;8:154-7.
87. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Tovarone) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-7.
88. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-32.
89. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15.
90. Chi CC, Wang SH, Kirtschig G, Wojnarowska F. Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol 2010;62:694-705.
91. Friedlander SF, Hebert AA, Allen DB; Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-93.
92. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations. Am J Clin Dermatol 2009;10:397-406.
93. Poulin Y, Papp K, Bissonnette R, Guenther L, Van der Heijden M, et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010;21:185-92.
94. Binderup L, Bramm E. Effects of a novel Vitamin D analogue MC903 on cell proliferation and differentiation in vivo and on calcium metabolism in vitro. Biochem Pharmacol 1988;37:889-95.
95. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. Calcipotriene study group. J Am Acad Dermatol 1995;32:67-72.
96. Ramsay CA. Management of psoriasis with calcipotriol used as monotherapy. J Am Acad Dermatol 1997;37(3 Pt 2):S53-4.
97. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009;(2):CD005028.
98. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis: A randomized, double-blind trial. Br J Dermatol 1994;130:483-7.
99. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations. Am J Clin Dermatol 2009;10:397-406.
100. Poulin Y, Papp K, Bissonnette R, Guenther L, Van der Heijden M, et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010;21:185-92.
101.Bindoff J, Bramm E. Effects of a novel Vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988;37:889-95.
102. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. Calcipotriene study group. J Am Acad Dermatol 1995;32:67-72.
103. Ramsay CA. Management of psoriasis with calcipotriol used as monotherapy. J Am Acad Dermatol 1997;37(3 Pt 2):S53-4.
104. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009;(2):CD005028.
homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg 2016;20:44-51.

101. Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg/g ointment. Br J Dermatol. 2001;144 Suppl 58:17-9.

102. van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Hönigsmann H, Marks R, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002;146:414-22.

103. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997;137:581-6.

104. Trémezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Dermatoendocrinol 2011;3:180-6.

105. Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010;11:1999-2009.

106. Pérez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:238-46.

107. Kragbelle K. Vitamin D3 analogues. Dermatol Clin 1996;13:835-8.

108. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38(6 Pt 1):1010-1.

109. Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 1996;135:390-3.

110. Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003;31:21-8.

111. Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1 alpha, 25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: A pilot study. Br J Dermatol 2004;151:190-5.

112. Helfrich YR, Kang S, Hamilton TA, Voorhees JJ. Topical becocalcidiol for the treatment of psoriasis vulgaris: A randomized, placebo-controlled, double-blind, multicentre study. Br J Dermatol 2007;157:369-74.